Lassen Therapeutics Presents Phase I Data on LASN01, an IL-11 Receptor-Blocking Antibody for Treatment of Pulmonary Fibrosis, at the American Thoracic Society 2023 Annual Meeting

SAN DIEGO–(BUSINESS WIRE)–Lassen Therapeutics, a clinical stage biotech company developing first-in-class antibody therapeutics targeting interleukin-11 receptor (IL-11R, LASN01) as a potential treatment for fibro-inflammatory diseases including thyroid eye disease (TED) and interleukin-18 binding protein (IL-18BP, LASN500) as a potential treatment for cancer, presented new preclinical and Phase I data of LASN01 for treatment of pulmonary fibrosis, at today’s American Thoracic Society (ATS) A
Click here to view original post